TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
Hirsutism
Key Statistics
- 5–10% — Women of reproductive age affected
- >70% — Of cases caused by PCOS
- 0.2% — Cases due to ovarian/adrenal tumour
Don't-miss facts
-
Post-menopausal woman with new-onset severe hirsutism → TVS mandatory to exclude ovarian hyperthecosis and ovarian tumour; refer urgently if testosterone ≥3 nmol/L
-
Urgent endocrine referral: testosterone ≥6 nmol/L (pre-menopausal), sudden onset, rapid progression, pelvic/abdominal mass, virilisation (voice, muscle bulk, clitoromegaly)
-
COC first line if fertility not sought; off-label except Dianette; high VTE risk → EE 20 µg + low-risk progestin
-
Add antiandrogen only after 6 months of COC monotherapy fails — combination is not standard first line; all antiandrogens feminise a male fetus (contraception mandatory)
-
Flutamide → hepatotoxicity (liver transplant); CPA → VTE; spironolactone → hyperkalaemia; finasteride only partially effective
-
Allow 6 months to detect and 9 months for maximal treatment effect — do not switch early
-
Metformin is no better than placebo for hirsutism; reserve for PCOS + type 2 diabetes failing lifestyle or unable to take COC
-
NCCAH screening in high-risk women (family history; Ashkenazi Jewish, Hispanic, Eastern European): 17- hydroxyprogesterone in follicular phase (random if irregular/amenorrhoeic)
Ferriman–gallwey cutoffs by ethnicity
UK/US Black or White ≥8 Mediterranean/Hispanic/Middle Eastern ≥9 South American ≥6 Far/SE Asian ≥3
Han Chinese ≥2 Southern Chinese ≥7
Quick recall
5–10% prevalence · PCOS >70% of cases · tumours 0.2% (~50% malignant) · idiopathic hirsutism 5–20% Hair cycle: anagen 2–7 y, catagen 3 wk, telogen 3 mo, exogen 2–5 mo; facial anagen ~4 months Testosterone binding: 70–80% SHBG, 20–30% albumin; bioavailable = free + albumin-bound “Permanent” reduction = ≥30% terminal hair loss sustained beyond one growth cycle (4–12 months) Eflornithine 11.5%: results 6–8 weeks; apply ≥5 min after hair removal; avoid in pregnancy/breastfeeding/<19 years NCCAH prevalence: Ashkenazi Jewish 3.7%, Central European 2%, White 0.1% Pregnancy: theca lutein cysts 10–20% with trophoblastic disease; 30% virilise; luteoma resolves within weeks postpartum
Abbreviation Key
- PCOS — polycystic ovary syndrome
- EE — ethinyl estradiol
- FGS — Ferriman–Gallwey score
- CPA — cyproterone acetate
- SHBG — sex hormone-binding globulin
- ESHRE — European Society of Human Reproduction and Embryology
- COC — combined oral contraceptive
- LC–MS/MS — liquid chromatography–tandem mass spectrometry
- DHEAS — dehydroepiandrosterone sulfate
- TVS — transvaginal sonography
- NCCAH — non-classical congenital adrenal hyperplasia
- VTE — venous thromboembolism
- OHT — ovarian hyperthecosis
- HAIR-AN — hyperandrogenism, insulin resistance, acanthosis nigricans
- GnRHa — gonadotrophin-releasing hormone analogue/agonist
- hCG — human chorionic gonadotrophin
Source: Sundararajan S et al. Hirsutism: a guide for the obstetrician and gynaecologist. The Obstetrician & Gynaecologist 2025;27:122–134. doi:10.1111/tog.12974
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).